Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men.

Abstract

Animals immunized with native or recombinant envelope proteins from the human immunodeficiency virus (HIV, formerly referred to as human T-lymphotropic virus type III) human T-lymphotropic virus type IIIB and naturally HIV-infected men were assessed for neutralizing antibodies and cell-mediated immunity toward the virus. Immunization of rabbits or goats with the native external envelope glycoprotein gpl20 or with corresponding recombinant proteins elicited strictly type-speciflic neutralizing antibodies. A broad, group-specific cellular immune response to gpl20 and to three different HIV isolates was seen in goats immunized with the native gpl20 but not in animals immunized with the nonglycosylated recombinant envelope proteins. In HIV-infected people, no T-cell response was seen, even though their T-cell response toward other foreign antigens was intact. The results show type-and group-speciflic epitopes on gpl20, some of which may be of importance for the development of a vaccine against HIV infection.

Immunoregulatory activities of human immunodeficiency virus (HIV) proteins: effect of HIV recombinant and synthetic peptides on immunoglobulin synthesis and proliferative responses by normal lymphocytes.

“…Recently Zarling et al (17) demonstrated T-cell responses to gpl20 in macaques, and Cease et al (18), employing an emphipathic helix model, demonstrated Thelper sites on env peptides in mice. In an animal model, Krohn et al (19) observed T-cell proliferative responses to native gpl20 but not to recombinant env peptides. The lack ofT-cell responses to recombinant peptides may be due to the lack of immunogenic epitopes in the preparation.…”

“…Briefly, wells of polystyrene plates were coated with 0.1 ml of heavy chain-specific rabbit anti-human IgG diluted to 2 gg/ml in 0.05 M sodium carbonate (pH 9.6) containing 0.02% sodium azide. The plates were sealed, incubated at room temperature for [16][17][18][19][20] Fig. 3 demonstrate that human PBMC precultured with 5-200 ng of the env-gag protein per ml produced significant levels of IgG.…”

Immunizations of monkeys with synthetic peptides disclose conserved areas on gp120 of human immunodeficiency virus type 1 associated with cross-neutralizing antibodies and T-cell recognition.

“…HIV-1 neutralizing antibodies have been raised in experimental animals using native (5) and recombinant gp4l and gpl20 (1,6). Synthetic peptides derived from these proteins have been used as immunogens and have been shown to elicit a neutralizing antibody response (7)(8)(9)(10).…”

Induction of anti-human immunodeficiency virus (HIV) neutralizing antibodies in rabbits immunized with recombinant HIV--hepatitis B surface antigen particles.

“…The HIV determinants carried by recombinant 8 induced a better immune response than those carried by recombinant 2. According to the lower proportion of the fused protein in recombinant 8 (29), using a fused protein produced in E. coli carrying an overlapping sequence, also obtained neutralizing antibodies and a specific cellular immune response. In our HBsAg expression system, the proteins are normally glycosylated and this could be very important in eliciting high-affinity antibodies needed to block the interaction of the HIV envelope protein with the CD4 receptor.…”